Legal News 20 February 2026 - 15 May 2026

Fortescue Shares Face Test After A$150 Million Court Loss
····

Fortescue Shares Face Test After A$150 Million Court Loss

Fortescue Ltd starts Monday’s ASX session after miners slipped at the end of last week, and traders want to see if the recent rally holds up with a new native-title snag in play. The stock finished Friday at A$22.60, losing 1.7% for the session, but that’s still roughly 6.3% higher than last Friday’s close of A$21.27, according to historical trading data. Here’s the odd thing: shares ended up for the week, even as the legal news got worse.
May 17, 2026
Woolworths Group Ltd Faces Discount-Price Reckoning After Coles Court Loss
·····

Woolworths Group Ltd Faces Discount-Price Reckoning After Coles Court Loss

Friday brings Woolworths Group Ltd’s discount-pricing case back into the spotlight, following a Federal Court ruling that found rival Coles had misled customers with its “Down Down” campaign. Timing is key here. The judge is still weighing a separate case involving Woolworths, and the Australian Competition and Consumer Commission declined to comment while that’s pending. In Coles’ situation, the regulator said the case covered 245 products, and the court identified misleading claims on 13 out of 14 sample “Down Down” price tickets reviewed in the liability hearing.
May 15, 2026
GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight
······

GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight

A U.S. federal judge has tossed Acuitas Therapeutics Inc.’s attempt to shield Pfizer and BioNTech’s Comirnaty Covid-19 vaccine from GSK’s patent claims, handing the British pharma giant a procedural victory in the ongoing mRNA legal fight. Judge Gregory B. Williams sided with GSK, dismissing the Acuitas case on grounds that the court lacked subject-matter jurisdiction—essentially, it didn’t have the authority to weigh in as presented, according to Bloomberg Law on Friday. The decision keeps the spotlight fixed on the main Delaware showdown involving GSK, Pfizer and BioNTech, instead of letting a supplier-driven lawsuit muddy the waters. Back in 2024, GSK filed suit against Pfizer and BioNTech, claiming Comirnaty stepped on patents for mRNA vaccine technology the company says it created
May 9, 2026
JPMorgan Chase Faces Fresh Legal Pressure as Employee Drug-Cost Suit Moves Ahead
···

JPMorgan Chase Faces Fresh Legal Pressure as Employee Drug-Cost Suit Moves Ahead

A federal judge in Manhattan has let key claims move forward in a proposed class action that targets JPMorgan Chase over alleged mismanagement of its health and prescription benefits plan. According to the lawsuit, employees in the country’s biggest bank say they were charged too much for both drugs and premiums. This ruling drops into the middle of an escalating dispute over how large companies oversee drug-plan vendors. It comes on the heels of the U.S. Supreme Court’s April 2025 Cornell decision, which lowered the bar for workers to keep certain ERISA cases alive early on. ERISA is the federal law covering workplace benefit plans.
March 10, 2026